|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Involvement of PI3K/Aktpathway in cell cycle progression, apoptosis, and neoplastictransformation: a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 2 | Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 3 | Involvement of PI3K/AKT pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 4 | Involvement of PI32K/Akt pathway in cell cycle progression,apoptosis,and neopastic transformation:a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，59： | 1 |
| 5 | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors 显示文摘 | Steelman LS Navolanic PM Sokolosky ML | 2008 | Oncogene2008，27，2： | 1 |
| 6 | EGFR family signaling and its association with breast cancer development and resistance to chemotherapy显示文摘 | Navolanic PM Steelman LS McCubrey JA | 2003 | Int J Oncol2003，22，2： | 1 |
| 7 | Elitek-rasburicase:an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas 显示文摘 | Navolanic PM Pui CH Larson RA | 2003 | Leukemia2003，17，3： | 1 |
| 8 | lnvolvement of PI3-K/Akt pthway in cell cycle progression, apoptosis, and neoplastic transformation:a target for cancer chcmotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 9 | Involvement of PI3 K/Akt path- way in cell cycle progression, apoptosis, and neoplastic transforma- tion:a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 10 | Involvement of PI3K/Akt pathway in cell cycle progression, apotosis, and neoplatic transformation: a target for cancer chemotherapy 显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 11 | Involvement of PI3K/Akt path way in cell cycle progression, apoptosis, and neoplastic trans- formation: a target for cancer chemotherapy 显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 12 | Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 13 | Involvement of PI3K/ Akt pathway in cell cycle progression,apoptosis,and neoplastic transformation:a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 14 | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors 显示文摘 | Steelman LS Navolanic PM Sokolosky ML | 2008 | Oncogene2008，27，29： | 1 |
| 15 | Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy 显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 16 | Involvement of PI3K/Akt pathway in cell cycle progression,apoptosis and neoplastic transformation:a target for cancer chemotherapy显示文摘 | Chang F Lee JT Navolanic PM | 2003 | Leukemia2003，17，3： | 1 |
| 17 | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to roTOR inhibitors显示文摘 | Steelman LS Navolanic PM Sokolosky ML | 2008 | Oneogene2008，27，29： | 1 |
| 18 | EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) 显示文摘 | Navolanic PM Steelman LS Mccubrey JA | 2003 | lnt J Oncol2003，22，2： | 1 |
| 19 | Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Rport, Dallas, Texas, January2002显示文摘 | Navolanic PM Pui CH Larson RA | 2003 | Leukemia2003，17，3： | 1 |
| 20 | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to roTOR inhibitors 显示文摘 | Steelman LS Navolanic PM Sokolosky ML | 2008 | Oncogene2008，27，29： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员